Cyproterone Acetate

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 2061 Experts worldwide ranked by ideXlab platform

M. C. Meriggiola - One of the best experts on this subject based on the ideXlab platform.

  • Testosterone Undecanoate Maintains Spermatogenic Suppression Induced by Cyproterone Acetate Plus Testosterone Undecanoate in Normal Men
    2016
    Co-Authors: M. C. Meriggiola, A. Costantino, S. Cerpolini, W. J. Bremner, D. Huebler, A. M. Morselli-labate, B. Kirsch, A. Bertaccini, C. Pelusi, G. Pelusi
    Abstract:

    In this study we evaluated whether testosterone undecanoate (TU), alone or combined with low dose Cyproterone Acetate (CPA), can maintain spermatogenic suppression induced by higher doses of CPA plus TU. Twenty-four men received for 12 wk 20 mg/d CPA plus 1000 mg/6 wk TU and then 1000 mg/8 wk TU plus 20 mg/d CPA (n8), 2 mg/d CPA (n8), or plus placebo (n 8) for 32 wk. Blood samples, physical examinations, hor-mones, chemistry, hematology, semen analysis, and sexual/ behavioral assessments were performed throughout the study. Sperm counts decreased to less than 1 million/ml in all subjects by wk 12, and 54 % of them achieved azoospermia. Suppression of sperm counts was maintained until wk 44. Serum LH and FSH levels were suppressed by wk 12 of hor-mone administration and remained suppressed until wk 44. No significant changes in any biochemical parameters wer

  • testosterone undecanoate maintains spermatogenic suppression induced by Cyproterone Acetate plus testosterone undecanoate in normal men
    The Journal of Clinical Endocrinology and Metabolism, 2003
    Co-Authors: M. C. Meriggiola, A. Costantino, S. Cerpolini, W. J. Bremner, D. Huebler, B. Kirsch, A. Bertaccini, C. Pelusi, Antonio Maria Morsellilabate, G. Pelusi
    Abstract:

    In this study we evaluated whether testosterone undecanoate (TU), alone or combined with low dose Cyproterone Acetate (CPA), can maintain spermatogenic suppression induced by higher doses of CPA plus TU. Twenty-four men received for 12 wk 20 mg/d CPA plus 1000 mg/6 wk TU and then 1000 mg/8 wk TU plus 20 mg/d CPA (n = 8), 2 mg/d CPA (n = 8), or plus placebo (n = 8) for 32 wk. Blood samples, physical examinations, hormones, chemistry, hematology, semen analysis, and sexual/behavioral assessments were performed throughout the study. Sperm counts decreased to less than 1 million/ml in all subjects by wk 12, and 54% of them achieved azoospermia. Suppression of sperm counts was maintained until wk 44. Serum LH and FSH levels were suppressed by wk 12 of hormone administration and remained suppressed until wk 44. No significant changes in any biochemical parameters were detected at wk 44 in any group. There was a slight increase in total prostate volume to within the normal range at wk 44 that returned to baselin...

  • low dose of Cyproterone Acetate and testosterone enanthate for contraception in men
    Human Reproduction, 1998
    Co-Authors: M. C. Meriggiola, W. J. Bremner, Antonietta Costantino, G Di Cintio, C Flamigni
    Abstract:

    After a control phase, 10 normal men received Cyproterone Acetate (CPA) at a dose of 25 mg/day (CPA-25; n=5) or 12.5 mg/day (CPA-12.5; n=5) plus testosterone enanthate (TE) 100 mg/week, for 16 weeks. Throughout the study sperm counts were performed every 2 weeks, and luteinizing hormone (LH), follicle stimulating hormone (FSH), testosterone, biochemical and haematological tests were performed every 4 weeks. All five men in group CPA-25 and three men in group CPA-12.5 achieved azoospermia. One man in group CPA-25 was azoospermic by week 12 of hormone administration, but had a sperm count of 0.1 x 10(6)/ml at week 16. Time to azoospermia was 9.0+/-1.3 and 8.7+/-0.7 weeks in groups CPA-25 and CPA-12.5 respectively. Gonadotrophins were decreased by week 4 of hormone administration, remained around the minimum detectability of the assay for the duration of hormone administration and returned to baseline after stopping hormone administration. Testosterone values did not change. No change in any biochemical parameters was found. Haematological parameters were decreased at week 16 of hormone administration and returned to baseline after stopping hormone administration. In conclusion, these results suggest that an hormonal regimen consisting of testosterone plus a progestin with anti-androgenic properties holds promise as an effective, safe and reversible male contraceptive.

  • an oral regimen of Cyproterone Acetate and testosterone undecanoate for spermatogenic suppression in men
    Fertility and Sterility, 1997
    Co-Authors: M. C. Meriggiola, A. Costantino, W. J. Bremner, A Pavani, M Capelli, C Flamigni
    Abstract:

    Abstract Objective: To test the effectiveness, safety, and reversibility of the combined administration of Cyproterone Acetate and T undecanoate. Designt: Open clinical trial. Setting: Healthy volunteers in an academic research environment. Patient(s): Eight healthy men, aged 25–42 years were selected. Intervention(s): Cyproterone Acetate, 12.5 mg, and T undecanoate, 80 mg, were administered orally twice daily for 16 weeks. Main Outcome Measure(s): Semen analyses every 2 weeks; physical examination, chemistries, hematology, prostatic-specific antigen, gonadotropins and T levels, and a questionnaire on sexual and behavioral function every 4 weeks. Result(s): In all subjects a profound suppression of spermatogenesis occurred; one subject became azoospermic, five subjects had sperm counts of ≤3 X 10 6 /mL, and in two subjects sperm counts were 4 and 6 X 10 6 /mL in week 16. Sperm counts returned to baseline in all men after hormone administration was discontinued. No changes in metabolic parameters and total prostatic-specific antigen were detected. Hemoglobin and hematocrit decreased statistically significantly at week 16 of treatment and returned to baseline by week 12 of recovery. There was no change in sexual function or behavior. Conclusion(s): The oral administration of T undecanoate plus Cyproterone Acetate induces a profound suppression of spermatogenesis with no major adverse effects. These data suggest the feasibility of oral contraception in men.

W. J. Bremner - One of the best experts on this subject based on the ideXlab platform.

  • Testosterone Undecanoate Maintains Spermatogenic Suppression Induced by Cyproterone Acetate Plus Testosterone Undecanoate in Normal Men
    2016
    Co-Authors: M. C. Meriggiola, A. Costantino, S. Cerpolini, W. J. Bremner, D. Huebler, A. M. Morselli-labate, B. Kirsch, A. Bertaccini, C. Pelusi, G. Pelusi
    Abstract:

    In this study we evaluated whether testosterone undecanoate (TU), alone or combined with low dose Cyproterone Acetate (CPA), can maintain spermatogenic suppression induced by higher doses of CPA plus TU. Twenty-four men received for 12 wk 20 mg/d CPA plus 1000 mg/6 wk TU and then 1000 mg/8 wk TU plus 20 mg/d CPA (n8), 2 mg/d CPA (n8), or plus placebo (n 8) for 32 wk. Blood samples, physical examinations, hor-mones, chemistry, hematology, semen analysis, and sexual/ behavioral assessments were performed throughout the study. Sperm counts decreased to less than 1 million/ml in all subjects by wk 12, and 54 % of them achieved azoospermia. Suppression of sperm counts was maintained until wk 44. Serum LH and FSH levels were suppressed by wk 12 of hor-mone administration and remained suppressed until wk 44. No significant changes in any biochemical parameters wer

  • testosterone undecanoate maintains spermatogenic suppression induced by Cyproterone Acetate plus testosterone undecanoate in normal men
    The Journal of Clinical Endocrinology and Metabolism, 2003
    Co-Authors: M. C. Meriggiola, A. Costantino, S. Cerpolini, W. J. Bremner, D. Huebler, B. Kirsch, A. Bertaccini, C. Pelusi, Antonio Maria Morsellilabate, G. Pelusi
    Abstract:

    In this study we evaluated whether testosterone undecanoate (TU), alone or combined with low dose Cyproterone Acetate (CPA), can maintain spermatogenic suppression induced by higher doses of CPA plus TU. Twenty-four men received for 12 wk 20 mg/d CPA plus 1000 mg/6 wk TU and then 1000 mg/8 wk TU plus 20 mg/d CPA (n = 8), 2 mg/d CPA (n = 8), or plus placebo (n = 8) for 32 wk. Blood samples, physical examinations, hormones, chemistry, hematology, semen analysis, and sexual/behavioral assessments were performed throughout the study. Sperm counts decreased to less than 1 million/ml in all subjects by wk 12, and 54% of them achieved azoospermia. Suppression of sperm counts was maintained until wk 44. Serum LH and FSH levels were suppressed by wk 12 of hormone administration and remained suppressed until wk 44. No significant changes in any biochemical parameters were detected at wk 44 in any group. There was a slight increase in total prostate volume to within the normal range at wk 44 that returned to baselin...

  • low dose of Cyproterone Acetate and testosterone enanthate for contraception in men
    Human Reproduction, 1998
    Co-Authors: M. C. Meriggiola, W. J. Bremner, Antonietta Costantino, G Di Cintio, C Flamigni
    Abstract:

    After a control phase, 10 normal men received Cyproterone Acetate (CPA) at a dose of 25 mg/day (CPA-25; n=5) or 12.5 mg/day (CPA-12.5; n=5) plus testosterone enanthate (TE) 100 mg/week, for 16 weeks. Throughout the study sperm counts were performed every 2 weeks, and luteinizing hormone (LH), follicle stimulating hormone (FSH), testosterone, biochemical and haematological tests were performed every 4 weeks. All five men in group CPA-25 and three men in group CPA-12.5 achieved azoospermia. One man in group CPA-25 was azoospermic by week 12 of hormone administration, but had a sperm count of 0.1 x 10(6)/ml at week 16. Time to azoospermia was 9.0+/-1.3 and 8.7+/-0.7 weeks in groups CPA-25 and CPA-12.5 respectively. Gonadotrophins were decreased by week 4 of hormone administration, remained around the minimum detectability of the assay for the duration of hormone administration and returned to baseline after stopping hormone administration. Testosterone values did not change. No change in any biochemical parameters was found. Haematological parameters were decreased at week 16 of hormone administration and returned to baseline after stopping hormone administration. In conclusion, these results suggest that an hormonal regimen consisting of testosterone plus a progestin with anti-androgenic properties holds promise as an effective, safe and reversible male contraceptive.

  • an oral regimen of Cyproterone Acetate and testosterone undecanoate for spermatogenic suppression in men
    Fertility and Sterility, 1997
    Co-Authors: M. C. Meriggiola, A. Costantino, W. J. Bremner, A Pavani, M Capelli, C Flamigni
    Abstract:

    Abstract Objective: To test the effectiveness, safety, and reversibility of the combined administration of Cyproterone Acetate and T undecanoate. Designt: Open clinical trial. Setting: Healthy volunteers in an academic research environment. Patient(s): Eight healthy men, aged 25–42 years were selected. Intervention(s): Cyproterone Acetate, 12.5 mg, and T undecanoate, 80 mg, were administered orally twice daily for 16 weeks. Main Outcome Measure(s): Semen analyses every 2 weeks; physical examination, chemistries, hematology, prostatic-specific antigen, gonadotropins and T levels, and a questionnaire on sexual and behavioral function every 4 weeks. Result(s): In all subjects a profound suppression of spermatogenesis occurred; one subject became azoospermic, five subjects had sperm counts of ≤3 X 10 6 /mL, and in two subjects sperm counts were 4 and 6 X 10 6 /mL in week 16. Sperm counts returned to baseline in all men after hormone administration was discontinued. No changes in metabolic parameters and total prostatic-specific antigen were detected. Hemoglobin and hematocrit decreased statistically significantly at week 16 of treatment and returned to baseline by week 12 of recovery. There was no change in sexual function or behavior. Conclusion(s): The oral administration of T undecanoate plus Cyproterone Acetate induces a profound suppression of spermatogenesis with no major adverse effects. These data suggest the feasibility of oral contraception in men.

Monika Schaferkorting - One of the best experts on this subject based on the ideXlab platform.

  • Cyproterone Acetate loading to lipid nanoparticles for topical acne treatment particle characterisation and skin uptake
    Pharmaceutical Research, 2007
    Co-Authors: Jana Stecova, W Mehnert, Tobias Blaschke, Burkhard Kleuser, Ramadurai Sivaramakrishnan, Christos C Zouboulis, Holger Seltmann, Hans Christian Korting, K D Kramer, Monika Schaferkorting
    Abstract:

    Purpose Topical Cyproterone Acetate (CPA) treatment of skin diseases should reduce side effects currently excluding the use in males and demanding contraceptive measures in females. To improve skin penetration of the poorly absorbed drug, we intended to identify the active moiety and to load it to particulate carrier systems.

  • Cyproterone Acetate loading to lipid nanoparticles for topical acne treatment particle characterisation and skin uptake
    Pharmaceutical Research, 2007
    Co-Authors: Jana Stecova, W Mehnert, Tobias Blaschke, Burkhard Kleuser, Ramadurai Sivaramakrishnan, Christos C Zouboulis, Holger Seltmann, Hans Christian Korting, K D Kramer, Monika Schaferkorting
    Abstract:

    Topical Cyproterone Acetate (CPA) treatment of skin diseases should reduce side effects currently excluding the use in males and demanding contraceptive measures in females. To improve skin penetration of the poorly absorbed drug, we intended to identify the active moiety and to load it to particulate carrier systems. CPA metabolism in human fibroblasts, keratinocytes and a sebocyte cell line as well as androgen receptor affinity of native CPA and the hydrolysis product Cyproterone were determined. CPA 0.05% loaded solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), a nanoemulsion and micropheres were characterized for drug-particle interaction and CPA absorption using human skin ex-vivo. Native CPA proved to be the active agent. Application of CPA attached to SLN increased skin penetration at least four-fold over the uptake from cream and nanoemulsion. Incorporation into the lipid matrix of NLC and microspheres resulted in a 2–3-fold increase in CPA absorption. Drug amounts within the dermis were low with all preparations. No difference was seen in the penetration into intact and stripped skin. With particulate systems topical CPA treatment may be an additional therapeutic option for acne and other diseases of the pilosebaceous unit.

A. Costantino - One of the best experts on this subject based on the ideXlab platform.

  • Testosterone Undecanoate Maintains Spermatogenic Suppression Induced by Cyproterone Acetate Plus Testosterone Undecanoate in Normal Men
    2016
    Co-Authors: M. C. Meriggiola, A. Costantino, S. Cerpolini, W. J. Bremner, D. Huebler, A. M. Morselli-labate, B. Kirsch, A. Bertaccini, C. Pelusi, G. Pelusi
    Abstract:

    In this study we evaluated whether testosterone undecanoate (TU), alone or combined with low dose Cyproterone Acetate (CPA), can maintain spermatogenic suppression induced by higher doses of CPA plus TU. Twenty-four men received for 12 wk 20 mg/d CPA plus 1000 mg/6 wk TU and then 1000 mg/8 wk TU plus 20 mg/d CPA (n8), 2 mg/d CPA (n8), or plus placebo (n 8) for 32 wk. Blood samples, physical examinations, hor-mones, chemistry, hematology, semen analysis, and sexual/ behavioral assessments were performed throughout the study. Sperm counts decreased to less than 1 million/ml in all subjects by wk 12, and 54 % of them achieved azoospermia. Suppression of sperm counts was maintained until wk 44. Serum LH and FSH levels were suppressed by wk 12 of hor-mone administration and remained suppressed until wk 44. No significant changes in any biochemical parameters wer

  • testosterone undecanoate maintains spermatogenic suppression induced by Cyproterone Acetate plus testosterone undecanoate in normal men
    The Journal of Clinical Endocrinology and Metabolism, 2003
    Co-Authors: M. C. Meriggiola, A. Costantino, S. Cerpolini, W. J. Bremner, D. Huebler, B. Kirsch, A. Bertaccini, C. Pelusi, Antonio Maria Morsellilabate, G. Pelusi
    Abstract:

    In this study we evaluated whether testosterone undecanoate (TU), alone or combined with low dose Cyproterone Acetate (CPA), can maintain spermatogenic suppression induced by higher doses of CPA plus TU. Twenty-four men received for 12 wk 20 mg/d CPA plus 1000 mg/6 wk TU and then 1000 mg/8 wk TU plus 20 mg/d CPA (n = 8), 2 mg/d CPA (n = 8), or plus placebo (n = 8) for 32 wk. Blood samples, physical examinations, hormones, chemistry, hematology, semen analysis, and sexual/behavioral assessments were performed throughout the study. Sperm counts decreased to less than 1 million/ml in all subjects by wk 12, and 54% of them achieved azoospermia. Suppression of sperm counts was maintained until wk 44. Serum LH and FSH levels were suppressed by wk 12 of hormone administration and remained suppressed until wk 44. No significant changes in any biochemical parameters were detected at wk 44 in any group. There was a slight increase in total prostate volume to within the normal range at wk 44 that returned to baselin...

  • an oral regimen of Cyproterone Acetate and testosterone undecanoate for spermatogenic suppression in men
    Fertility and Sterility, 1997
    Co-Authors: M. C. Meriggiola, A. Costantino, W. J. Bremner, A Pavani, M Capelli, C Flamigni
    Abstract:

    Abstract Objective: To test the effectiveness, safety, and reversibility of the combined administration of Cyproterone Acetate and T undecanoate. Designt: Open clinical trial. Setting: Healthy volunteers in an academic research environment. Patient(s): Eight healthy men, aged 25–42 years were selected. Intervention(s): Cyproterone Acetate, 12.5 mg, and T undecanoate, 80 mg, were administered orally twice daily for 16 weeks. Main Outcome Measure(s): Semen analyses every 2 weeks; physical examination, chemistries, hematology, prostatic-specific antigen, gonadotropins and T levels, and a questionnaire on sexual and behavioral function every 4 weeks. Result(s): In all subjects a profound suppression of spermatogenesis occurred; one subject became azoospermic, five subjects had sperm counts of ≤3 X 10 6 /mL, and in two subjects sperm counts were 4 and 6 X 10 6 /mL in week 16. Sperm counts returned to baseline in all men after hormone administration was discontinued. No changes in metabolic parameters and total prostatic-specific antigen were detected. Hemoglobin and hematocrit decreased statistically significantly at week 16 of treatment and returned to baseline by week 12 of recovery. There was no change in sexual function or behavior. Conclusion(s): The oral administration of T undecanoate plus Cyproterone Acetate induces a profound suppression of spermatogenesis with no major adverse effects. These data suggest the feasibility of oral contraception in men.

G. Pelusi - One of the best experts on this subject based on the ideXlab platform.

  • Testosterone Undecanoate Maintains Spermatogenic Suppression Induced by Cyproterone Acetate Plus Testosterone Undecanoate in Normal Men
    2016
    Co-Authors: M. C. Meriggiola, A. Costantino, S. Cerpolini, W. J. Bremner, D. Huebler, A. M. Morselli-labate, B. Kirsch, A. Bertaccini, C. Pelusi, G. Pelusi
    Abstract:

    In this study we evaluated whether testosterone undecanoate (TU), alone or combined with low dose Cyproterone Acetate (CPA), can maintain spermatogenic suppression induced by higher doses of CPA plus TU. Twenty-four men received for 12 wk 20 mg/d CPA plus 1000 mg/6 wk TU and then 1000 mg/8 wk TU plus 20 mg/d CPA (n8), 2 mg/d CPA (n8), or plus placebo (n 8) for 32 wk. Blood samples, physical examinations, hor-mones, chemistry, hematology, semen analysis, and sexual/ behavioral assessments were performed throughout the study. Sperm counts decreased to less than 1 million/ml in all subjects by wk 12, and 54 % of them achieved azoospermia. Suppression of sperm counts was maintained until wk 44. Serum LH and FSH levels were suppressed by wk 12 of hor-mone administration and remained suppressed until wk 44. No significant changes in any biochemical parameters wer

  • testosterone undecanoate maintains spermatogenic suppression induced by Cyproterone Acetate plus testosterone undecanoate in normal men
    The Journal of Clinical Endocrinology and Metabolism, 2003
    Co-Authors: M. C. Meriggiola, A. Costantino, S. Cerpolini, W. J. Bremner, D. Huebler, B. Kirsch, A. Bertaccini, C. Pelusi, Antonio Maria Morsellilabate, G. Pelusi
    Abstract:

    In this study we evaluated whether testosterone undecanoate (TU), alone or combined with low dose Cyproterone Acetate (CPA), can maintain spermatogenic suppression induced by higher doses of CPA plus TU. Twenty-four men received for 12 wk 20 mg/d CPA plus 1000 mg/6 wk TU and then 1000 mg/8 wk TU plus 20 mg/d CPA (n = 8), 2 mg/d CPA (n = 8), or plus placebo (n = 8) for 32 wk. Blood samples, physical examinations, hormones, chemistry, hematology, semen analysis, and sexual/behavioral assessments were performed throughout the study. Sperm counts decreased to less than 1 million/ml in all subjects by wk 12, and 54% of them achieved azoospermia. Suppression of sperm counts was maintained until wk 44. Serum LH and FSH levels were suppressed by wk 12 of hormone administration and remained suppressed until wk 44. No significant changes in any biochemical parameters were detected at wk 44 in any group. There was a slight increase in total prostate volume to within the normal range at wk 44 that returned to baselin...

Related terms

Cyproterone Acetate - 15 days free trial to Access Experts & Abstracts